Vas Narasimhan, Novartis CEO (Gian Ehrenzeller/Keystone via AP Images)
January 11, 2024 02:43 PM EST
Deals

No­var­tis re­port­ed­ly backs off ac­qui­si­tion of Cy­to­ki­net­ics – WSJ

Katherine Lewin

News Reporter

Af­ter No­var­tis CEO Vas Narasimhan down­played ru­mors that his com­pa­ny want­ed to ac­quire the biotech Cy­to­ki­net­ics, the Wall Street Jour­nal re­port­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times